Clinical trials: Unresectable Stage III Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer (NSCLC), in combination with a novel agent cetuximab.
- Trial name
- NCT00193453
- Testing
- Gemcitabine, Docetaxel, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Advanced stage lung cancer is generally treated with anti-cancer medication called chemotherapy. Most lung cancer is caused by cigarette smoking.
- Trial name
- NCT00988169
- Testing
- oral erlotinib and pulsed doses of oral AT-101
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
This trial studies the side effects and how well nintedanib works compared to a placebo in treating against radiation-induced pneumonitis (inflammation of the lungs) in patients with non-small cell lung cancer that cannot be…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Radiation-Induced Pneumonitis, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
- Trial name
- NCT02452463
- Testing
- Durvalumab, Nintedanib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Non-small Cell Lung Cancer
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per…
- Trial name
- DUART (NCT04249362)
- Testing
- Durvalumab
- Where
- 35 sites in United States, France and 4 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies the effect of bintrafusp alfa with pemetrexed and platinum-based chemotherapy (carboplatin or cisplatin) in treating patients with EGFR mutant non-small cell lung cancer that have spread to nearby…
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT04971187
- Testing
- Bintrafusp Alfa, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
This is a Phase 3, randomized, double-blind, placebo-controlled multicenter global study designed to compare the efficacy and safety of tislelizumab in combination with concurrent chemoradiotherapy (cCRT) followed by tislelizumab…
- Trial name
- RATIONALE001 (NCT03745222)
- Testing
- Tislelizumab, Concurrent chemoradiotherapy (cCRT)
- Where
- 164 sites in United States, Belgium and 21 more
- Volunteers
- 1 people
- Sponsor
- Celgene
Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma
Resiliency Among Older Adults Receiving Lung Cancer Treatment
This trial studies how well physical therapy and progressive muscle relaxation works in improving physical performance and mood in older patients with stage IIIA-B or IV lung cancer who are undergoing treatment.
- Conditions
- Advanced Lung Carcinoma, Extensive Stage Lung Small Cell Carcinoma, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- ROAR-LCT (NCT04229381)
- Testing
- Physical Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab…
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03801902
- Testing
- Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography
- Where
- 56 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
To assess the 2 year survival of patients with Stage III unresectable non-small cell lung cancer receiving consolidation gemcitabine or gemcitabine plus docetaxel following concurrent chemotherapy and radiation.
- Trial name
- NCT00191139
- Testing
- gemcitabine, docetaxel, cisplatin
- Where
- 15 sites in United States, Argentina and 2 more
- Volunteers
- 64 people
- Sponsor
- Eli Lilly and Company
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Non Small Cell Lung Cancer (Stage III)
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
- Trial name
- LAURA (NCT03521154)
- Testing
- Osimertinib 80mg/40mg
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
The primary objective is to document the safety of tecemotide (L-BLP25) phase III formulation in non-small cell lung cancer (NSCLC) subjects with unresectable Stage III disease.
- Trial name
- NCT00157196
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best standard of care (BSC)
- Volunteers
- 22 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Lung Cancer, Non-Small Cell Lung Cancer
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung…
- Trial name
- NCT00094835
- Testing
- Panitumumab, Motesanib diphosphate, Paclitaxel
- Volunteers
- 51 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
This study is to determine if Stage III NSCLC patients treated with ipilimumab with thoracic radiation therapy followed by nivolumab monotherapy every 4 weeks for up to 12 months show an improved 12-month Progression Free…
- Trial name
- NCT03663166
- Testing
- Thoracic Radiotherapy, Platinum Based Chemotherapy, ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
This phase II trial studies how well MLN4924 (pevonedistat), carboplatin, and paclitaxel work in treating patients with stage IIIB or IV non-small cell lung cancer.
- Conditions
- Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03965689
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)